ILARIS canakinumab 150 mg powder for injection

Država: Australija

Jezik: engleski

Izvor: Department of Health (Therapeutic Goods Administration)

Aktivni sastojci:

Canakinumab, Quantity: 150 mg

Dostupno od:

Novartis Pharmaceuticals Australia Pty Ltd

INN (International ime):

Canakinumab

Farmaceutski oblik:

Injection, powder for

Sastav:

Excipient Ingredients: sucrose; histidine; histidine hydrochloride monohydrate; polysorbate 80; dilute hydrochloric acid

Administracija rute:

Subcutaneous

Jedinice u paketu:

1, 4

Tip recepta:

(S4) Prescription Only Medicine

Terapijske indikacije:

Ilaris is indicated for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), in adults and children aged 2 years or older including: Familial Cold Autoinflammatory Syndrome (FCAS) /Familial Cold Urticaria (FCU); Muckle-Wells Syndrome (MWS); Neonatal-Onset Multisystem Inflammatory Disease (NOMID) / Chronic Infantile Neurological, Cutaneous, Articular Syndrome (CINCA). Ilaris is indicated for the treatment of active Systemic Juvenile Idiopathic Arthritis (sJIA) in patients aged 2 years or older.

Proizvod sažetak:

Visual Identification: White solid lyophilisate; Container Type: Vial; Container Material: Glass Type I Clear; Container Life Time: 36 Months; Container Temperature: Store at 2 to 8 degrees Celsius

Status autorizacije:

Registered

Datum autorizacije:

2010-05-10